The above considerations indicate that YAP and TAZ play an important role in regulating tumor immunity in NSCLC, particularly through the direct transcriptional control of the immune checkpoint PD-L1, and that the combination of YAP/TAZ-targeting agents with PD-1/PD-L1 inhibitors may be a promising therapeutic strategy in the management of NSCLC patients, which could enhance the efficacy of immune checkpoint inhibitors. Here, PDCD1 is linked to neoplasm.